Tissue inhibitor of metalloproteinase-1 levels in plasma from tumour arteries and veins of patients with rectal cancer
- PMID: 17763191
- DOI: 10.1080/00365510601166926
Tissue inhibitor of metalloproteinase-1 levels in plasma from tumour arteries and veins of patients with rectal cancer
Abstract
Objective: Tissue inhibitor of metalloproteinase-1 (TIMP-1) plays a major role in the regulation of tissue growth, including cancer growth. The TIMP-1 protein can be determined in plasma, and increased plasma levels of TIMP-1 are associated with a poor prognosis of colorectal cancer patients. The aim of the present study was to evaluate whether tumour tissue release of the TIMP-1 protein contributes to the increased plasma levels of TIMP-1 observed in patients with colorectal cancer.
Material and methods: Preoperative blood samples from a peripheral vein and intraoperative blood samples from a tumour artery, a tumour vein and from a peripheral vein were drawn from 24 patients undergoing elective, intended curative surgery for primary rectal cancer. TIMP-1 levels were determined concurrently in plasma from all samples using a validated ELISA method. Counts of white blood cells and platelets were also carried out.
Results: No significant differences between plasma TIMP-1 levels could be demonstrated in any compartment. In particular, there was no significant difference in TIMP-1 levels in plasma from tumour arteries and tumour veins. However, there was a significant decrease in neutrophil cell counts from tumour arteries to tumour veins (p<0.001).
Conclusions: The present results do not support the current hypothesis that tumour cells contribute substantially to increased plasma TIMP-1 levels observed in patients with colorectal cancer.
Similar articles
-
Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer.Scand J Gastroenterol. 2008;43(2):186-91. doi: 10.1080/00365520701491355. Scand J Gastroenterol. 2008. PMID: 18224564
-
Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer.Clin Cancer Res. 2002 Jan;8(1):156-64. Clin Cancer Res. 2002. PMID: 11801553
-
High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.Clin Cancer Res. 2000 Nov;6(11):4292-9. Clin Cancer Res. 2000. PMID: 11106246
-
Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment.Scand J Gastroenterol. 2008;43(7):774-86. doi: 10.1080/00365520701878163. Scand J Gastroenterol. 2008. PMID: 18584515 Review.
-
Tissue inhibitor of metalloproteinases-1 in breast cancer.Endocr Relat Cancer. 2005 Jun;12(2):215-27. doi: 10.1677/erc.1.00719. Endocr Relat Cancer. 2005. PMID: 15947098 Review.
Cited by
-
Matrix metalloproteinases: protective roles in cancer.J Cell Mol Med. 2011 Jun;15(6):1254-65. doi: 10.1111/j.1582-4934.2011.01302.x. J Cell Mol Med. 2011. PMID: 21418514 Free PMC article. Review.
-
Matrix metalloproteinase-9 expression in the normal mucosa-adenoma-dysplasia-adenocarcinoma sequence of the colon.Pathol Oncol Res. 2008 Mar;14(1):31-7. doi: 10.1007/s12253-008-9004-5. Epub 2008 Mar 18. Pathol Oncol Res. 2008. PMID: 18347934
-
Banking of biological fluids for studies of disease-associated protein biomarkers.Mol Cell Proteomics. 2008 Oct;7(10):2061-6. doi: 10.1074/mcp.R800010-MCP200. Epub 2008 Aug 1. Mol Cell Proteomics. 2008. PMID: 18676364 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous